%0 Journal Article
%T Dysregulated miR-183 inhibits migration in breast cancer cells
%A Aoife J Lowery
%A Nicola Miller
%A Roisin M Dwyer
%A Michael J Kerin
%J BMC Cancer
%D 2010
%I BioMed Central
%R 10.1186/1471-2407-10-502
%X MiR-183 expression was quantitated in primary breast tumours, tumour associated normal tissue and breast cancer cell lines using RQ-PCR. Gain of function analysis was performed in breast cancer cells using pre-miR-183 and the effect of miR-183 overexpression on cell viability, proliferation, apoptosis and migration was examined. Customized Taqman Low Density Arrays (TLDA) were used to identify dysregulated genes in breast cancer cells transfected with pre-miR-183.We demonstrate that miR-183 is dysregulated in breast cancer and expression correlates with estrogen receptor and HER2/neu receptor expression. Induced overexpression of miR-183 inhibited migration of breast cancer cells. This finding was substantiated by RQ-PCR of mRNA from cells overexpressing miR-183 which showed dysregulation of several migration and invasion related genes. Specifically, the VIL2-coding protein Ezrin was confirmed as a target of miR-183 and downregulation of this protein was confirmed with immunocytochemistry.These findings indicate that miR-183 targets VIL2 and may play a central role in the regulation of migration and metastasis in breast cancer. Consequently, this miRNA may present an attractive target for therapeutic intervention.Breast cancer is a heterogeneous disease and represents a number of phenotypically diverse tumours[1]. The complex nature of breast cancer makes progression difficult to predict and challenging to manage. Up to forty percent of breast cancer patients still present with regional or distant disease progression at the time of diagnosis[2], and the overall survival rates for these patients has changed very little in the past decade despite advances in systemic therapy.The key to optimising breast cancer management lies in early detection, effective prognostication and individualised therapy, all of which demand a comprehensive understanding of the complex molecular interactions that underlie breast cancer development and progression. Gene expression profiling h
%U http://www.biomedcentral.com/1471-2407/10/502